Adrenaline
Adrenaline
CLINICAL USE
Sympathomimetic and inotropic agent
DOSE IN NORMAL RENAL FUNCTION
1–20 micrograms/minute
PHARMACOKINETICS
Molecular weight :
183.2
%Protein binding :
50
%Excreted unchanged in urine :
1
Volume of distribution (L/kg) :
No data
half-life – normal/ESRD (hrs) :
Phase 1: 3 minutes;
Phase 2: 10 minutes
DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50 : Dose as in normal renal function
10 to 20 : Dose as in normal renal function
<10 :
Dose as in normal renal function
DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD :
Not dialysed. Dose as in normal renal function
HD :
Not dialysed. Dose as in normal renal function
HDF/high flux :
Unknown dialysability. Dose as in
normal renal function
CAV/VVHD :
Not dialysed. Dose as in normal renal function
IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs
Alpha-blockers: avoid with tolazoline
Anaesthetics: increased risk of
arrhythmias if given with volatile
anaesthetics
Antidepressants: increased risk of
arrhythmias and hypertension if given
with tricyclics; MAOIs and moclobemide
may cause hypertensive crisis.
Beta-blockers: increased risk of severe
hypertension
Clonidine: possible increased risk of
hypertension
Dopaminergics: effects possibly increased
by entacapone; avoid concomitant use
with rasagiline
Sympathomimetics: effects possibly
enhanced by dopexamine
ADMINISTRATION
Reconstition
1 mg in 100 mL glucose 5%
6 mL/hour = 1 microgram/minute –
according to local protocol
Route
IV, IM, SC
Rate of Administration
Monitor blood pressure and adjust dose
according to response
Comments
–
OTHER INFORMATION
Catecholamines have a high non-renal
systemic clearance; therefore the effect of
any renal replacement therapy is unlikely
to be relevant
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home
